Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Heterozygous Familial Hypercholesterolemia (HeFH):~-Completed Study 20120123 (NCT02392559) while still on assigned investigational product and did not experience a treatment-related serious adverse event~Homozygous Familial Hypercholesterolemia (HoFH):~* Male or female, ≥ 10 to ≤ 17 years of age at time of enrollment~* Diagnosis of HoFH~* On a low-fat diet and receiving background lipid-lowering therapy~* Lipid-lowering therapy unchanged for ≥ 4 weeks prior to LDL-C screening; fibrates must be stable for at least 6 weeks prior to screening.~* Fasting LDL-C at screening ≥ 130 mg/dL (3.4 mmol/L)~* Fasting triglycerides ≤ 400 mg/dL (4.5 mmol/L)~Exclusion Criteria:~-Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s); except Study 20120123~HoFH:~* Moderate to severe renal dysfunction~* Active liver disease or hepatic dysfunction,~* Creatine kinase \> 3 times the upper limit of normal (ULN) at screening

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Evolocumab (Type: EXPERIMENTAL): Participants receive 420 mg evolocumab administered by subcutaneous injection every 4 weeks (QM) for up to 80 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).